Abstract
Although functional selectivity is now widely accepted, the molecular basis is poorly understood. We have studied how aspects of transmembrane region 5 (TM5) of the dopamine D2L receptor interacts with three rationally selected rigid ligands (dihydrexidine, dinapsoline, and dinoxyline) and the reference compounds dopamine and quinpirole. As was expected from homology modeling, mutation of three TM5 serine residues to alanine (S5.42A, S5.43A, S5.46A) had little effect on antagonist affinity. All three mutations decreased the affinity of the agonist ligands to different degrees, S5.46A being somewhat less affected. Four functions [adenylate cyclase (AC), extracellular signal-regulated kinase 1/2 phosphorylation (MAPK), arachidonic acid release (AA), and guanosine 5′-O-(3-thio)triphosphate binding (GTPγS)] were assessed. The intrinsic activity (IA) of quinpirole was unaffected by any of the mutations, whereas S5.42A and S5.46A mutations abolished the activity of dopamine and the three rigid ligands, although dihydrexidine retained IA at MAPK function only with S5.42A. Remarkably, S5.43A did not markedly affect IA for AC and MAPK for any of the ligands and eliminated AA activity for dinapsoline and dihydrexidine but not dinoxyline. These data suggest that this mutation did not disrupt the overall conformation or signaling ability of the mutant receptors but differentially affected ligand activation. Computational studies indicate that these D2 agonists stabilize multiple receptor conformations. This has led to models showing the stabilized conformations and interhelical and receptor-ligand contacts corresponding to the different activation pathways stabilized by various agonists. These data provide a basis for understanding D2L functional selectivity and rationally discovering functionally selective D2 drugs.
Footnotes
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported by the National Institutes of Health National Institute of Mental Health [Grants MH082441; MH040537]; and by a Pennsylvania Keystone Innovation Grant.
The intellectual property for some of the compounds used in this study were assigned by R.B.M. to the University of North Carolina and licensed to Biovalve Technologies Inc., which was acquired by Valeritas.
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
ABBREVIATIONS:
- CHO
- Chinese hamster ovary
- DNS
- dinapsoline
- AC
- adenylate cyclase
- AA
- arachidonic acid release
- MAPK
- mitogen-activated protein kinase
- AA
- arachidonic acid
- DNX
- dinoxyline
- DHX
- dihydrexidine
- DA
- dopamine
- GPCR
- G protein-coupled receptor
- PMSF
- phenylmethylsulfonyl fluoride
- TM
- transmembrane
- WT
- wild type
- GTPγS
- guanosine 5′-O-(3-thio)triphosphate
- BSA
- bovine serum albumin
- PBS
- phosphate-buffered saline
- nH
- Hill coefficient
- K0.5
- apparent affinity constant (nH < 1.0), equals KI when nH = 1
- HD2L
- human dopamine D2L receptor
- BE
- binding energy
- HB
- hydrogen bond
- PDB
- protein data bank
- ANOVA
- analysis of variance.
- Received September 1, 2011.
- Accepted March 13, 2012.
- Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|